Cynata Therapeutics Limited
OTC: CYYNF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kilian Kelly
- Employees
- 2
- Headquarters
- Cremorne, Australia
- IPO year
- 2015
- Market cap
- $2.2M
- Website
- https://www.cynata.com
Loading CYYNF…
Loading profile data…Frequently asked questions about CYYNF
What does Cynata Therapeutics Limited (CYYNF) do?
Cynata Therapeutics Limited, an Australian biotechnology company headquartered in Cremorne, specializes in developing and bringing to market its unique Cymerus™ mesenchymal stem cell (MSC) technology for a wide array of human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully completed Phase I clinical t...
Where does CYYNF trade?
Cynata Therapeutics Limited (CYYNF) trades on the Other OTC.
What sector is CYYNF in?
Cynata Therapeutics Limited (CYYNF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cynata Therapeutics Limited?
Kilian Kelly is the chief executive officer of Cynata Therapeutics Limited (CYYNF).
Where is Cynata Therapeutics Limited headquartered?
Cynata Therapeutics Limited is headquartered in Australia.
Does CYYNF pay a dividend?
Cynata Therapeutics Limited (CYYNF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYYNF go public?
Cynata Therapeutics Limited (CYYNF) completed its initial public offering in 2015.